secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001213900-26-035499
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma shareholders re-elect 11 directors, ratify auditor, approve equity plan increase at 2026 annual meeting
--------------------------------------------------------------------------------

- All 11 incumbent directors re-elected with overwhelming support (over 98% for each nominee).
- Ratification of Simon & Edward, LLP as independent auditor for FY 2026: 10,597,352 for, 12,291 against.
- Equity incentive plan increase approved: 9,964,400 for, 643,419 against; shares reserved now 15% of outstanding.
- Quorum established with 10,612,493 shares (41.74% of voting power) present.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390026035499/0001213900-26-035499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390026035499/ea028361801-8k_abvcbiopharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-035499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer